Last reviewed · How we verify
BEAM
BEAM is a Small molecule drug developed by National Cancer Institute (NCI). It is currently FDA-approved. Also known as: Carmustine, Cytarabine, Etoposide, Melphalan.
Here's a 2-sentence factual summary of BEAM: BEAM is a combination of bevacizumab, temozolomide, and external beam radiation therapy used as first-line therapy in treating patients with brain and central nervous system tumors. BEAM has also been studied in treating other conditions, including diabetic macular edema, medulloblastoma, recurrent lung non-small cell carcinoma, and stage IV non-small cell lung cancer.
At a glance
| Generic name | BEAM |
|---|---|
| Also known as | Carmustine, Cytarabine, Etoposide, Melphalan, ASCT |
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1,PHASE2)
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue (NA)
- Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma (NA)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- SBRT Boost for Unfavorable Prostate Cancer' (NA)
- Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEAM CI brief — competitive landscape report
- BEAM updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about BEAM
What is BEAM?
Who makes BEAM?
Is BEAM also known as anything else?
What development phase is BEAM in?
Related
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Carmustine, Cytarabine, Etoposide, Melphalan, ASCT
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing